Viu E, Zapata A, Capdevila J L, Fossom L H, Skolnick P, Trullas R
Department of Bioanalítica Mèdica, Institut d'Investigacions Biomèdiques de Barcelona, Spain.
J Pharmacol Exp Ther. 1998 May;285(2):527-32.
Activation of N-methyl-D-aspartate (NMDA) receptors is known to produce arachidonic acid release, which has been implicated in excitotoxicity. Antagonists and partial agonists at the glycine site of the NMDA receptor, despite exhibiting functional differences in electrophysiological studies, inhibit glutamate-induced neurotoxicity and ischemia-induced neurodegeneration. The objective of this study was to investigate the effects of both glycine site antagonists and partial agonists on NMDA receptor-mediated [3H]arachidonic acid (AA) release evoked by glutamate, NMDA or a competitive inhibitor of the glutamate/aspartate uptake carrier. The [3H]AA release evoked by a maximally effective concentration of glutamate (100 microM) was blocked by the glycine site antagonists 7-chlorokynurenic acid (7-CKYN) and 5,7-dichlorokynurenic acid (5,7-DCKYN) and by a low intrinsic efficacy glycine partial agonist (+)-1-hydroxy-3-aminopyrrolid-2-one [(+)-HA-966]. 1-Aminocyclopropanecarboxylic acid (ACPC), a high intrinsic efficacy glycine partial agonist, did not modify [3H]AA release evoked by 100 microM glutamate. However, ACPC blocked (in a glycine reversible manner) the [3H]AA release induced by NMDA (100 microM) with an IC50 of 131 +/- 2 microM. Furthermore, L-trans-pyrrolidine-2,4-dicarboxylate (PDC), a competitive inhibitor of the glutamate transporter, also released [3H]AA (Emax and EC50 of 127 +/- 4% and 30 +/- 1 microM, respectively). ACPC, 7-CKYN and (+/-)-2-amino-7-phosphonoheptanoic acid (AP-7), a competitive NMDA receptor antagonist, inhibited [3H]AA release evoked by PDC. These results demonstrate that both glycine site antagonists and partial agonists can inhibit NMDA receptor-mediated [3H]AA release in cerebellar granule cells, an action consistent with the neuroprotective effects of these compounds.
已知N-甲基-D-天冬氨酸(NMDA)受体的激活会导致花生四烯酸释放,这与兴奋性毒性有关。NMDA受体甘氨酸位点的拮抗剂和部分激动剂,尽管在电生理研究中表现出功能差异,但能抑制谷氨酸诱导的神经毒性和缺血诱导的神经退行性变。本研究的目的是研究甘氨酸位点拮抗剂和部分激动剂对谷氨酸、NMDA或谷氨酸/天冬氨酸摄取载体竞争性抑制剂诱发的NMDA受体介导的[3H]花生四烯酸(AA)释放的影响。最大有效浓度的谷氨酸(100μM)诱发的[3H]AA释放被甘氨酸位点拮抗剂7-氯犬尿氨酸(7-CKYN)和5,7-二氯犬尿氨酸(5,7-DCKYN)以及低内在效能的甘氨酸部分激动剂(+)-1-羟基-3-氨基吡咯烷-2-酮[(+)-HA-966]阻断。高内在效能的甘氨酸部分激动剂1-氨基环丙烷羧酸(ACPC)并未改变100μM谷氨酸诱发的[3H]AA释放。然而,ACPC以甘氨酸可逆的方式阻断了NMDA(100μM)诱导的[3H]AA释放,IC50为131±2μM。此外,谷氨酸转运体的竞争性抑制剂L-反式-脯氨酸-2,4-二羧酸(PDC)也能释放[3H]AA(Emax和EC50分别为127±4%和30±1μM)。ACPC、7-CKYN和竞争性NMDA受体拮抗剂(±)-2-氨基-7-磷酸庚酸(AP-7)抑制了PDC诱发的[3H]AA释放。这些结果表明,甘氨酸位点拮抗剂和部分激动剂均可抑制小脑颗粒细胞中NMDA受体介导的[3H]AA释放,这一作用与这些化合物的神经保护作用一致。